Drug Delivery for Cardiovascular Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 8213
Special Issue Editor
Interests: bone; cell cycle; akt; Ca2+-activated K+(BK) channel; calcium ions; cell volume; trp channels; KATP and Kir channels
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Small molecules are used to treat cardiovascular system diseases (CVDs), and different formulations have been developed to improve solubility, PK, and efficacy/safety. Examples of classically used drugs include diltiazem, isosorbide-5-mononitrate, metoprolol, propafenone, and aspirin. Formulations of valsartan, atenolol, atorvastatin, and ezetemide have recently been developed. Emerging evidence indicates that nano-drug delivery systems (NDDSs) have the ability to increase stability and water drug solubility, increase the uptake of target cells, improve the PK, and can be used to deliver biologics and small molecules by various routes. NDDSs may improve the effectiveness of drugs in CVDs. However, less attention has been dedicated to safety. Nanomaterials can be highly reactive, generating ROS and affecting macromolecules, which leads to cell growth inhibition or cell cycle modification. In special populations including old people with chronic CVDs or in neonatal/pediatric patients affected by rare diseases, the efficacy and safety of these formulations need to be evaluated.
Prof. Dr. Domenico Tricarico
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nano-drug delivery systems
- neonatal and pediatric population
- aged people affected by chronic CVD
- efficacy
- tolerability and safety
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
